Bank of New York Mellon Corp Buys 1,169 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Bank of New York Mellon Corp lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 765,411 shares of the biopharmaceutical company’s stock after buying an additional 1,169 shares during the period. Bank of New York Mellon Corp’s holdings in Regeneron Pharmaceuticals were worth $591,387,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of REGN. Nordea Investment Management AB increased its stake in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after buying an additional 74,350 shares during the period. Lockheed Martin Investment Management Co. acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $2,702,000. Asio Capital LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $3,422,000. Robeco Institutional Asset Management B.V. boosted its holdings in Regeneron Pharmaceuticals by 116.6% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after acquiring an additional 140,966 shares during the last quarter. Finally, National Pension Service increased its position in Regeneron Pharmaceuticals by 29.8% during the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after purchasing an additional 82,853 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on REGN. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Canaccord Genuity Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Leerink Partners restated a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Finally, Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $787.67.

Regeneron Pharmaceuticals Stock Up 2.2%

Regeneron Pharmaceuticals stock opened at $678.94 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The firm’s fifty day moving average is $641.76 and its 200 day moving average is $718.70. The company has a market capitalization of $71.78 billion, a PE ratio of 16.54, a PEG ratio of 1.47 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period last year, the company posted $8.22 earnings per share. The business’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.